JPMorgan Chase & Co. Sells 158,615 Shares of Hologic, Inc. $HOLX

JPMorgan Chase & Co. reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 12.5% in the third quarter, Holdings Channel.com reports. The fund owned 1,108,008 shares of the medical equipment provider’s stock after selling 158,615 shares during the period. JPMorgan Chase & Co.’s holdings in Hologic were worth $74,783,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in HOLX. The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares during the last quarter. Invesco Ltd. increased its holdings in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares in the last quarter. Geode Capital Management LLC raised its position in Hologic by 1.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in Hologic by 26.1% during the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after acquiring an additional 832,444 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Hologic by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock valued at $201,364,000 after acquiring an additional 66,453 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 0.1%

NASDAQ:HOLX opened at $75.35 on Wednesday. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.49. The business has a fifty day moving average price of $74.93 and a 200-day moving average price of $72.02. The firm has a market capitalization of $16.82 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm posted $0.87 earnings per share. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HOLX shares. Morgan Stanley boosted their price objective on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research note on Friday, November 21st. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.